Literature DB >> 22787208

Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys.

Jeffrey E Teigler1, M Justin Iampietro, Dan H Barouch.   

Abstract

Adenovirus (Ad) vaccine vectors have proven highly immunogenic in multiple experimental models, but the innate immune responses induced by these vectors remain poorly characterized. Here we report innate cytokine responses to 5 different Ad vectors in 26 rhesus monkeys. Vaccination with adenovirus serotype 35 (Ad35), Ad26, and Ad48 induced substantially higher levels of antiviral (gamma interferon [IFN-γ], 10-kDa gamma interferon-induced protein [IP-10]) and proinflammatory (interleukin 1 receptor antagonist [IL-1RA], IL-6) cytokines than vaccination with Ad5 on day 1 following immunization. In vitro studies with capsid chimeric vectors and receptor-blocking monoclonal antibodies suggested that fiber-receptor interactions, as well as other capsid components, were critical for triggering these innate responses. Moreover, multiple cell populations, including dendritic cells, monocytes/macrophages, and T lymphocytes, contributed to these innate cytokine profiles. These data demonstrate that Ad35, Ad26, and Ad48, which utilize CD46 as their primary cellular receptor, induce significantly greater innate cytokine responses than Ad5, which uses the coxsackievirus and adenovirus receptor (CAR). These differences in innate triggering result in markedly different immunologic milieus for the subsequent generation of adaptive immune responses by these vaccine vectors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22787208      PMCID: PMC3446581          DOI: 10.1128/JVI.00740-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease.

Authors:  M J E Havenga; A A C Lemckert; O J A E Ophorst; M van Meijer; W T V Germeraad; J Grimbergen; M A van Den Doel; R Vogels; J van Deutekom; A A M Janson; J D de Bruijn; F Uytdehaag; P H A Quax; T Logtenberg; M Mehtali; A Bout
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

2.  Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages.

Authors:  Y Zhang; N Chirmule; G P Gao; R Qian; M Croyle; B Joshi; J Tazelaar; J M Wilson
Journal:  Mol Ther       Date:  2001-05       Impact factor: 11.454

3.  Activation of innate immunity in nonhuman primates following intraportal administration of adenoviral vectors.

Authors:  M A Schnell; Y Zhang; J Tazelaar; G P Gao; Q C Yu; R Qian; S J Chen; A N Varnavski; C LeClair; S E Raper; J M Wilson
Journal:  Mol Ther       Date:  2001-05       Impact factor: 11.454

4.  Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes.

Authors:  Hiroyuki Mizuguchi; Takao Hayakawa
Journal:  Gene       Date:  2002-02-20       Impact factor: 3.688

5.  Preexisting immunity to adenovirus in rhesus monkeys fails to prevent vector-induced toxicity.

Authors:  Andrei N Varnavski; Yi Zhang; Michael Schnell; John Tazelaar; Jean-Pierre Louboutin; Qian-Chun Yu; Adam Bagg; Guang-ping Gao; James M Wilson
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.

Authors:  Olga J A E Ophorst; Stefan Kostense; Jaap Goudsmit; Rik L De Swart; Sandra Verhaagh; Alexander Zakhartchouk; Marja Van Meijer; Mieke Sprangers; Geert Van Amerongen; Selma Yüksel; Albert D M E Osterhaus; Menzo J E Havenga
Journal:  Vaccine       Date:  2004-08-13       Impact factor: 3.641

7.  A monoclonal antibody specific for the cellular receptor for the group B coxsackieviruses.

Authors:  K H Hsu; K Lonberg-Holm; B Alstein; R L Crowell
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

8.  CD46 is a cellular receptor for group B adenoviruses.

Authors:  Anuj Gaggar; Dmitry M Shayakhmetov; André Lieber
Journal:  Nat Med       Date:  2003-10-19       Impact factor: 53.440

9.  Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells.

Authors:  Maria L Barilla-LaBarca; M Kathryn Liszewski; John D Lambris; Dennis Hourcade; John P Atkinson
Journal:  J Immunol       Date:  2002-06-15       Impact factor: 5.422

10.  Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake.

Authors:  Oliver Meier; Karin Boucke; Silvija Vig Hammer; Stephan Keller; Robert P Stidwill; Silvio Hemmi; Urs F Greber
Journal:  J Cell Biol       Date:  2002-09-09       Impact factor: 10.539

View more
  72 in total

Review 1.  Getting genetic access to natural adenovirus genomes to explore vector diversity.

Authors:  Wenli Zhang; Anja Ehrhardt
Journal:  Virus Genes       Date:  2017-07-15       Impact factor: 2.332

2.  The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys.

Authors:  Jeffrey E Teigler; Sanjay Phogat; Genoveffa Franchini; Vanessa M Hirsch; Nelson L Michael; Dan H Barouch
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

3.  Homologous recombination in E3 genes of human adenovirus species D.

Authors:  Gurdeep Singh; Christopher M Robinson; Shoaleh Dehghan; Morris S Jones; David W Dyer; Donald Seto; James Chodosh
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

Review 4.  New developments in an old strategy: heterologous vector primes and envelope protein boosts in HIV vaccine design.

Authors:  Thomas Musich; Marjorie Robert-Guroff
Journal:  Expert Rev Vaccines       Date:  2016-03-16       Impact factor: 5.217

5.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors:  Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

6.  Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.

Authors:  Patricia A Darrah; Diane L Bolton; Andrew A Lackner; Deepak Kaushal; Pyone Pyone Aye; Smriti Mehra; James L Blanchard; Peter J Didier; Chad J Roy; Srinivas S Rao; David A Hokey; Charles A Scanga; Donata R Sizemore; Jerald C Sadoff; Mario Roederer; Robert A Seder
Journal:  J Immunol       Date:  2014-07-14       Impact factor: 5.422

7.  Conformational changes in the adenovirus hexon subunit responsible for regulating cytoplasmic dynein recruitment.

Authors:  Julian Scherer; Richard B Vallee
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

8.  An attenuated Listeria monocytogenes vector primes more potent simian immunodeficiency virus-specific mucosal immunity than DNA vaccines in mice.

Authors:  Eung-Jun Im; Erica N Borducchi; Nicholas M Provine; Anna G McNally; Sufen Li; Fred R Frankel; Dan H Barouch
Journal:  J Virol       Date:  2013-02-06       Impact factor: 5.103

9.  Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.

Authors:  Camilla Patrizia Hrycak; Sonja Windmann; Wibke Bayer
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

10.  Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Reduces Acute HIV-1 Viremia.

Authors:  Daniel T Claiborne; Timothy E Dudek; Colby R Maldini; Karen A Power; Musie Ghebremichael; Edward Seung; Elizabeth F Mellors; Vladimir D Vrbanac; Katharine Krupp; Abigail Bisesi; Andrew M Tager; David M Knipe; Christian L Boutwell; Todd M Allen
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.